TY - JOUR
T1 - Comparison of serum matrix metalloproteinase-9 value in spondylitis tuberculous with degenerative spine disease
AU - Siregar, Otman
AU - Augustinus, Yohanes
AU - Benny, Benny
AU - Rahyussalim, Ahmad Jabir
N1 - Publisher Copyright:
© 2020 Otman Siregar, Yohanes Augustinus, Benny Benny, Ahmad Jabir Rahyussalim.
PY - 2020/1/2
Y1 - 2020/1/2
N2 - AIM: We aimed to evaluate and compare the expression of MMP-9 in TB spondylitis using serum levels in the blood of patients suffering from TB spondylitis and compared to the control group; in this case, the control group in this study was patients with degenerative diseases of the spine. METHODS: Fourteen subjects were divided into two groups, with seven subjects of spondylitis tuberculous (TB) (ST) and seven subjects of degenerative spine disease (DSD) in the period from December 2017 to November 2018 who were included in the inclusion criteria included in this study and blood sampling was taken for the examination of serum matrix metalloproteinase-9 (MMP-9) levels. RESULTS: There were significant differences in serum MMP-9 levels between ST and DSDs with a significance value of 0.002 (p < 0.05) with low serum MMP-9 levels in the ST study group 1857.14 ± 377.96 and mean in the control group 857.14 ± 243.97. There were significant differences in serum MMP-9 levels between ST and DSDs with a significance value of 0.002 (p < 0.05) with low serum MMP-9 levels in the ST study group 1857.14 ± 377.96 and mean in the control group 857.14 ± 243.97. CONCLUSION: Patients suffering from ST have higher serum MMP-9 levels than patients with DSD, although MMP-9 is not a specific marker examination for ST, the results of this study can be suggestive into that can help to evaluate enzyme activity in patients with ST disease.
AB - AIM: We aimed to evaluate and compare the expression of MMP-9 in TB spondylitis using serum levels in the blood of patients suffering from TB spondylitis and compared to the control group; in this case, the control group in this study was patients with degenerative diseases of the spine. METHODS: Fourteen subjects were divided into two groups, with seven subjects of spondylitis tuberculous (TB) (ST) and seven subjects of degenerative spine disease (DSD) in the period from December 2017 to November 2018 who were included in the inclusion criteria included in this study and blood sampling was taken for the examination of serum matrix metalloproteinase-9 (MMP-9) levels. RESULTS: There were significant differences in serum MMP-9 levels between ST and DSDs with a significance value of 0.002 (p < 0.05) with low serum MMP-9 levels in the ST study group 1857.14 ± 377.96 and mean in the control group 857.14 ± 243.97. There were significant differences in serum MMP-9 levels between ST and DSDs with a significance value of 0.002 (p < 0.05) with low serum MMP-9 levels in the ST study group 1857.14 ± 377.96 and mean in the control group 857.14 ± 243.97. CONCLUSION: Patients suffering from ST have higher serum MMP-9 levels than patients with DSD, although MMP-9 is not a specific marker examination for ST, the results of this study can be suggestive into that can help to evaluate enzyme activity in patients with ST disease.
KW - Degenerative spine disease
KW - Matrix metalloproteinase
KW - Spondylitis tuberculous
UR - http://www.scopus.com/inward/record.url?scp=85097440180&partnerID=8YFLogxK
U2 - 10.3889/oamjms.2020.4258
DO - 10.3889/oamjms.2020.4258
M3 - Article
AN - SCOPUS:85097440180
SN - 1857-5749
VL - 8
SP - 619
EP - 622
JO - Open Access Macedonian Journal of Medical Sciences
JF - Open Access Macedonian Journal of Medical Sciences
ER -